'Groundbreaking' two-in-one prostate cancer drug which 'halves the risk' of the disease progressing

'Groundbreaking' two-in-one prostate cancer drug which 'halves the risk' of the disease progressing A treatment described as groundbreaking could benefit hundreds of men with advanced prostate cancer if approved in the UK.

Trials have shown a combination of two drugs – enzalutamide and talazoparib – can halve the risk of prostate cancer progressing.

The treatment is part of a class of new precision medications which allow tumours to be targeted more accurately. The Daily Mail

See also:

• Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial (abstract) The Lancet